TRACON Pharmaceuticals (TCON) Receiving Somewhat Negative Press Coverage, Report Shows

Headlines about TRACON Pharmaceuticals (NASDAQ:TCON) have trended somewhat negative this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.8546559957806 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern’s analysis:

Shares of TRACON Pharmaceuticals remained flat at $$2.50 during trading hours on Friday, according to Marketbeat Ratings. The company had a trading volume of 55,669 shares, compared to its average volume of 106,704. TRACON Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $3.95. The company has a current ratio of 4.24, a quick ratio of 4.24 and a debt-to-equity ratio of 0.15. The company has a market cap of $44.38 million, a PE ratio of -2.19 and a beta of 2.06.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). TRACON Pharmaceuticals had a negative return on equity of 82.47% and a negative net margin of 201.21%. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.00 million. analysts anticipate that TRACON Pharmaceuticals will post -1.42 earnings per share for the current fiscal year.

A number of brokerages recently issued reports on TCON. Needham & Company LLC cut their target price on TRACON Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a report on Thursday, May 10th. ValuEngine upgraded TRACON Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd.

In related news, major shareholder Enterprise Associates 14 New purchased 707,964 shares of the stock in a transaction that occurred on Tuesday, March 27th. The stock was acquired at an average cost of $2.70 per share, with a total value of $1,911,502.80. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 23.30% of the company’s stock.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD.

Insider Buying and Selling by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply